Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Liabilities and Shareholders Equity (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 10.78% to $3.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 billion through Dec 2025, down 7.92% year-over-year, with the annual reading at $3.6 billion for FY2025, 10.78% down from the prior year.
  • Liabilities and Shareholders Equity hit $3.6 billion in Q4 2025 for Integra Lifesciences Holdings, down from $3.6 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.1 billion in Q1 2024 to a low of $3.6 billion in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $3.8 billion across 5 years, with a median of $3.8 billion in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 9.46% in 2021 and later fell 10.78% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $3.8 billion in 2021, then grew by 2.84% to $3.9 billion in 2022, then dropped by 2.77% to $3.8 billion in 2023, then increased by 6.75% to $4.0 billion in 2024, then dropped by 10.78% to $3.6 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for IART at $3.6 billion in Q4 2025, $3.6 billion in Q3 2025, and $3.7 billion in Q2 2025.